Calibrate is a year-long, brand-only, coaching-intensive program with a $1,649-$1,999 upfront program fee plus separately billed medication; flat-rate compounded telehealth is typically far less expensive but without the structured coaching layer.
If cost and simplicity matter most, compounded tirzepatide at $297/month, flat, is a very different value proposition than Calibrate's model.
Calibrate and typical compounded-tirzepatide telehealth providers aren't really competing on the same terms — they're built around fundamentally different philosophies. Understanding that difference matters more than comparing headline prices directly.
How Calibrate's Program Works
Calibrate is structured as a 12-month "metabolic reset" combining brand-name GLP-1 prescribing (Wegovy or Zepbound, navigated through insurance) with intensive one-on-one coaching across food, exercise, sleep, and emotional health, plus mandatory lab testing at baseline and follow-up intervals. As of 2026, Calibrate has shifted to prescribing brand-name medication exclusively, having moved away from compounded options amid the broader regulatory tightening affecting compounded GLP-1s industry-wide. The annual program fee has been reported in the $1,649-$1,999 range, paid upfront or financed, with medication billed separately through insurance.
How Flat-Rate Compounded Telehealth Works
A flat-rate compounded telehealth model, like Luma Health's, centers on the medication itself: a real medical evaluation, ongoing dose management, and provider access for side-effect questions, at $297/month for tirzepatide, flat, regardless of dose. There's no year-long curriculum, no mandatory lab schedule, and no dedicated coaching staff — the price reflects a more streamlined, medical-first model.
Calibrate's structured coaching and lab-monitoring approach has genuine clinical merit — multimodal interventions combining medication with behavioral support do tend to produce better long-term outcomes in obesity medicine research. The question isn't whether that structure helps; it's whether you specifically want and will use that level of programming, or whether you'd rather get equivalent medical care with a lighter footprint and lower cost.
Running the Actual Cost Math
For a patient with insurance that covers Wegovy or Zepbound at a low copay, Calibrate's total annual cost (program fee plus copay) might land somewhere around $1,950-$2,300/year. For a patient without that coverage, brand-name medication cash cost would be added on top of the program fee, pushing the total considerably higher. Compounded tirzepatide at $297/month totals $3,564/year — more than flat-rate semaglutide, but still without a year-long commitment or mandatory program fee, and without requiring insurance coverage to be affordable.
Which Model Fits You
- Have insurance that covers Wegovy or Zepbound at an affordable copay
- Want intensive, structured coaching and regular lab monitoring built in
- Are comfortable with a 12-month program commitment
- Don't have insurance coverage for brand-name GLP-1s
- Want a simpler program without a year-long commitment
- Prefer month-to-month flexibility and lower total cost
Real medical care,
no year-long commitment
Compounded tirzepatide at $297/month, flat, month-to-month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
As of 2026, Calibrate has shifted to prescribing brand-name GLP-1 medication exclusively, moving away from compounded options amid broader industry regulatory changes.
The program fee has been reported in the $1,649-$1,999/year range, with medication billed separately through insurance — total cost depends heavily on your specific coverage.
For patients who want and will use intensive, structured behavioral coaching and regular lab monitoring, it can be genuinely valuable. For patients whose main need is medical treatment, that structure may not justify the added cost.
Calibrate's program is structured as a year-long commitment; confirm current cancellation and refund terms directly, as early cancellation may not be straightforward given the upfront program fee structure.
Since compounded tirzepatide contains the same active ingredient, the underlying pharmacological effect is the same. Effectiveness in practice depends on the compounding pharmacy's quality and following the same titration protocol.
It depends heavily on your insurance coverage. Without insurance covering brand medication, flat-rate compounded telehealth is typically considerably less expensive; with strong insurance coverage, Calibrate's total cost can be competitive for patients who also want the coaching structure.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com